|1.||Chen, Haipeng: 1 article (08/2011)|
|2.||Cui, Binbin: 1 article (08/2011)|
|3.||Wang, Xishan: 1 article (08/2011)|
|4.||Yu, Zhiwei: 1 article (08/2011)|
|5.||Jin, Yinghu: 1 article (08/2011)|
|6.||Lyerly, Herbert K: 1 article (05/2010)|
|7.||Ghanayem, Rami B: 1 article (05/2010)|
|8.||Devi, Gayathri R: 1 article (05/2010)|
|9.||Peplinski, Sharon: 1 article (05/2010)|
|10.||Aird, Katherine M: 1 article (05/2010)|
08/12/2011 - "In this study, using human colon adenocarcinoma HT29 and SW480 cells as research models, we compared the efficacy of four EGFR inhibitors in of EGFR-mediated pathways, including the novel irreversible inhibitor 324674, conventional reversible inhibitor AG1478, dual EGFR/HER2 inhibitor GW583340 and the pan-EGFR/ErbB2/ErbB4 inhibitor. "
05/01/2010 - "In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors. "
|1.||tyrphostin AG 1478
|2.||X-Linked Inhibitor of Apoptosis Protein